User profiles for Natasha T. Strande
Natasha T. StrandeSenior Associate Consultant, Mayo Verified email at mayo.edu Cited by 3724 |
[PDF][PDF] Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria
… In other words, the threshold for the supporting level of evidence was the smallest value t in
the prediction range such that for all scores s greater than or equal to t, the lower error bound …
the prediction range such that for all scores s greater than or equal to t, the lower error bound …
[PDF][PDF] Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium
…, S Punj, CS Richards, J Salama, NT Strande… - The American Journal of …, 2016 - cell.com
Evaluating the pathogenicity of a variant is challenging given the plethora of types of genetic
evidence that laboratories consider. Deciding how to weigh each type of evidence is difficult…
evidence that laboratories consider. Deciding how to weigh each type of evidence is difficult…
[PDF][PDF] Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource
With advances in genomic sequencing technology, the number of reported gene-disease
relationships has rapidly expanded. However, the evidence supporting these claims varies …
relationships has rapidly expanded. However, the evidence supporting these claims varies …
Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population
Importance VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory,
somatic) syndrome is a disease with rheumatologic and hematologic features caused by …
somatic) syndrome is a disease with rheumatologic and hematologic features caused by …
Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing …
…, SE Plon, HL Rehm, NT Strande… - The American Journal of …, 2023 - cell.com
The American College of Medical Genetics and Genomics (ACMG)/Association for Molecular
Pathology (AMP) framework for classifying variants uses six evidence categories related to …
Pathology (AMP) framework for classifying variants uses six evidence categories related to …
Organization and dynamics of the nonhomologous end-joining machinery during DNA double-strand break repair
…, G Watanabe, NT Strande… - Proceedings of the …, 2015 - National Acad Sciences
Nonhomologous end-joining (NHEJ) is a major repair pathway for DNA double-strand breaks
(DSBs), involving synapsis and ligation of the broken strands. We describe the use of in …
(DSBs), involving synapsis and ligation of the broken strands. We describe the use of in …
Nonhomologous end joining: a good solution for bad ends
CA Waters, NT Strande, DW Wyatt, JM Pryor… - DNA repair, 2014 - Elsevier
Double strand breaks pose unique problems for DNA repair, especially when broken ends
possess complex structures that interfere with standard DNA transactions. Nonhomologous …
possess complex structures that interfere with standard DNA transactions. Nonhomologous …
[HTML][HTML] The fidelity of the ligation step determines how ends are resolved during nonhomologous end joining
CA Waters, NT Strande, JM Pryor, CN Strom… - Nature …, 2014 - nature.com
Nonhomologous end joining (NHEJ) can effectively resolve chromosome breaks despite
diverse end structures; however, it is unclear how the steps employed for resolution are …
diverse end structures; however, it is unclear how the steps employed for resolution are …
[PDF][PDF] Genomic sequencing for newborn screening: results of the NC NEXUS project
…, C Gustafson, DM DeCristo, NT Strande… - The American Journal of …, 2020 - cell.com
Newborn screening (NBS) was established as a public health program in the 1960s and is
crucial for facilitating detection of certain medical conditions in which early intervention can …
crucial for facilitating detection of certain medical conditions in which early intervention can …
[HTML][HTML] A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing
…, CM Powell, MI Roche, C Skrzynia, NT Strande… - Genetics in …, 2016 - nature.com
Purpose: As genome-scale sequencing is increasingly applied in clinical scenarios, a wide
variety of genomic findings will be discovered as secondary or incidental findings, and there …
variety of genomic findings will be discovered as secondary or incidental findings, and there …